The FDA has introduced a new priority review voucher program for three psychedelic drug candidates, including psilocybin for depression, following President Trump's executive order to accelerate mental health treatments. This coincides with a large meta ...

The Food and Drug Administration (FDA) announced Friday it will fast-track reviews of three separate psychedelic drugs to treat mental health conditions like

After an executive order, the FDA announced it would prioritize the study of some psychedelic drugs for therapeutic use. Which did they choose and why?

The first drug for women suffering postpartum depression received federal approval on Tuesday, a move likely to pave the way for a wave of treatments to address a debilitating condition that is the most common complication of pregnancy. The drug works very ...

The US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression - making it the first FDA-approved oral pill in the United States specifically for postpartum depression, a serious mental illness that ...